Design, synthesis, and antiprotozoal evaluation of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives

Jean Guillona INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceCorrespondence[email protected]
View further author information

Anita Cohenb IRD, AP-HM, SSA, VITROME, Aix-Marseille University, Marseille, FranceView further author information

Clotilde Boudotc INSERM U1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, Université de Limoges, Limoges, FranceView further author information

Alessandra Vallea INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Vittoria Milanoa INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Rabindra Nath Dasa INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Aurore Guédina INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Stéphane Moreaua INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Luisa Rongad PREM UMR5254 – UPPA/CNRS, Technopole Hélioparc, Université de Pau, Pau, FranceView further author information

Solène Savrimoutoua INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Maxime Demourguesa INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Elodie Reviriegoa INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Sandra Rubioa INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Sandie Ferrieza INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, FranceView further author information

Patrice Agnameye UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,FranceView further author information

Cécile Pauce UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,FranceView further author information

Serge Moukhaf Université de Bordeaux, Laboratoire de Toxicologie et d'Hygiène Appliquée - INRA, UFR des Sciences Pharmaceutiques, Bordeaux, FranceView further author information

Pascale Dozolmef Université de Bordeaux, Laboratoire de Toxicologie et d'Hygiène Appliquée - INRA, UFR des Sciences Pharmaceutiques, Bordeaux, FranceView further author information

Sophie Da Nascimentoe UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,FranceView further author information

Pierre Laumaillée UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,FranceView further author information

Anne Bouchute UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,FranceView further author information

Nadine Azasb IRD, AP-HM, SSA, VITROME, Aix-Marseille University, Marseille, FranceView further author information

Jean-Louis Mergnya INSERM U1212, UMR CNRS 5320, ARNA Laboratory, UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France;g Institut Curie, Université Paris-Saclay, CNRS-UMR 9187, INSERM U1196, Université Paris-Saclay, Orsay, France;h Institute of Biophysics of the CAS, Brno, Czech RepublicView further author information

Catherine Mulliée UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,FranceView further author information

Pascal Sonnete UFR de Pharmacie, AGIR (Agents Infectieux, Résistance et chimiothérapie), Université de Picardie Jules Verne, Amiens,FranceView further author information

Bertrand Courtiouxc INSERM U1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, Université de Limoges, Limoges, FranceView further author information

show all

Design, synthesis, and antiprotozoal evaluation of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives

Articles from other publishers (14)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Design, synthesis, and antiprotozoal evaluation of new 2,4-bis[(substituted-aminomethyl)phenyl]quinoline, 1,3-bis[(substituted-aminomethyl)phenyl]isoquinoline and 2,4-bis[(substituted-aminomethyl)phenyl]quinazoline derivatives

Citations (14)

Articles from other publishers (14)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date